IBRX — ImmunityBio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1326110 ·
Last close
$7.92
Market Cap
$8.30B
52W High
$10.98
52W Low
$6.54
ADV30
14,138,745
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 44,206,000 | 43,968,000 | -69,791,000 | -632,782,000 | 646,637,000 | 205,194,000 | 1,515,763,000 |
| Dec 2025 | 38,285,000 | 37,903,000 | -64,683,000 | -61,944,000 | 501,898,000 | 88,334,000 | 1,001,472,000 |
| Sep 2025 | 32,061,000 | 31,884,000 | -55,630,000 | -67,253,000 | 518,987,000 | 60,241,000 | 1,042,397,000 |
| Jun 2025 | 26,425,000 | 26,289,000 | -71,285,000 | -92,555,000 | 402,076,000 | 137,658,000 | 971,895,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-304,936,000
Investing CF
$-149,801,000
Financing CF
$400,241,000
CapEx
$-4,252,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.38
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,726,646,000
Inventory
$910,000
Receivables
$42,617,000
ST Investments
$154,484,000
EBIT TTM
$-239,082,000
Pretax Income TTM
$-351,607,000
Interest Exp TTM
$112,525,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$140,976,992
EBITDA
$-245,412,992
Free Cash Flow
$-193,704,624
Enterprise Value
$8,306,504,704
Total Cash
$380,879,008
Total Debt
$1,124,608,000
Shares Out
1,047,353,977
Trailing EPS
$-0.85
Book Value
$-0.83
ROE
—
ROA
-34.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 113,288,000 | -256,027,000 | -351,398,000 | 501,898,000 | 1,001,472,000 | — | -304,936,000 |
| Dec 2024 | 14,745,000 | -344,182,000 | -413,564,000 | 382,933,000 | 871,062,000 | — | -391,236,000 |
| Dec 2023 | 622,000 | -361,364,000 | -583,196,000 | 504,452,000 | 1,090,389,000 | — | -366,757,000 |
| Dec 2022 | 240,000 | -350,617,000 | -416,567,000 | 362,356,000 | 812,176,000 | — | -337,509,000 |
TTM Snapshot
Revenues TTM
$6,372,000
NetIncome TTM
$-379,878,000
OpCashFlow TTM
$0
Assets (Latest)
$382,933,000
Forward EPS
$0.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HALO | HALOZYME THERAPEUTICS, INC. | $8.15B | $68.72 | — |
| KRYS | Krystal Biotech, Inc. | $8.92B | $302.68 | — |
| TECH | BIO-TECHNE Corp | $7.51B | $47.97 | — |
| QGEN | QIAGEN N.V. | $7.33B | $35.54 | — |
| PCVX | Vaxcyte, Inc. | $7.24B | $50.11 | — |
News headlines (Yahoo Finance, 1h cache)
IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 — Everything To Know About ImmunityBio’s Findings
2026-05-22 12:27 · Yahoo
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
2026-05-22 11:30 · Yahoo
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
2026-05-22 11:30 · Yahoo
Assessing ImmunityBio (IBRX) Valuation After FDA Approval For Anktiva And Share Price Cooldown
2026-05-20 20:09 · Yahoo
Why ImmunityBio Stock is Soaring Higher Today
2026-05-20 15:15 · Yahoo
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy
2026-05-20 13:53 · Yahoo
Exchange-Traded Funds, Equity Futures Advance Pre-Bell Wednesday Ahead of Nvidia Earnings Report
2026-05-20 13:13 · Yahoo
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
2026-05-20 00:30 · Yahoo
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
2026-05-19 14:45 · Yahoo
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
2026-05-19 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.